Bristol Myers inks protein degrader deal via Celgene team's link to seed-stage biotech
Bristol Myers Squibb is adding to its protein degrader lineup, which already includes the likes of A-Alpha Bio and Evotec, by linking arms with a little-known biotech that’s been communicating with the scientists at Celgene for the past few years.
The Big Pharma is investing in SyntheX and laying out a $550 million vision for the Bay Area seed-stage biotech that was just “a sketch on a napkin” in Toronto in 2016, co-founder and CEO Maria Soloveychik told Endpoints News in a preview of the Tuesday morning pact.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.